Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses

Roush, George C.a; Ernst, Michael E.b; Kostis, John B.c; Yeasmin, Shamimab; Sica, Domenic A.d

doi: 10.1097/HJH.0000000000000762
REVIEWS
Buy
SDC

Background: Potassium-sparing diuretics (PSDs) are valuable antihypertensives with additional benefits unrelated to control of systolic blood pressure (SBP). However, their key parameters affecting SBP and serum potassium are poorly defined, fostering underutilization.

Method: Consequently, we conducted systematic reviews and meta-analyses, yielding 3668 articles and ultimately 84 randomized comparisons.

Results: For office SBP, overall placebo-adjusted changes were triamterene –1.9 (low dose only), amiloride –9.9, spironolactone –13.2, and eplerenone –9.2. Differences in antihypertensive effect were due to potency rather than efficacy. Doubling amiloride, eplerenone, and spironolactone doses reduced SBP (95% confidence limits) on average by –2.3 (–3.1, –1.5). Relative antihypertensive potencies were spironolactone>amiloride>eplerenone. Spironolactone had significantly greater antihypertensive potency than amiloride, –4.0 (–7.4, –0.6), and eplerenone, –5.5 (–7.4, –3.6). Dose equivalencies were eplerenonespironolactone 4.5-to-1 (e.g., eplerenone 125∼spironolactone 25), amiloridespironolactone 3.3-to-1, and eplerenoneamiloride 1.4-to-1. Increases in serum potassium from amiloride and spironolactone at commonly used doses averaged 0.14–0.29 mEq/l; the dose doubling effect was 0.16 (0.10, 0.22). Spironolactone caused greater hyperkalemia than amiloride across their dose ranges: 0.14, P = 0.043. Seven features make important bias unlikely: a comprehensive literature search, adjustment for covariates, all models explaining 95–100% of the between-study variability, similar dose doubling effects among PSDs, two different methods giving the same potency sequence, similar results from double blind comparisons, and similar results for eplerenone versus spironolactone from analysing direct comparison data (i.e., no meta-regression) for office and 24-h SBP.

Conclusion: This synthesis accomplishes for PSDs what has already been achieved for thiazide-type diuretics and other antihypertensives and can guide the application of these underutilized medicines.

Supplemental Digital Content is available in the text

aUCONN School of Medicine and St. Vincent's Medical Center, Department of Medicine, Bridgeport, Connecticut,

bUniversity of Iowa Hospital and Clinics, Department of Family Medicine, Iowa City, Iowa,

cCardiovascular Institute, Rutgers-Robert Wood Johnson Medical School, Chairman, Department of Medicine, New Brunswick, New Jersey,

dDepartment of Medicine and Pharmacology, Virginia Commonwealth University, Richmond, Virginia, USA

Correspondence to George C. Roush, MD, FACP, St. Vincent's Medical Center, 2800 Main P.O. Box 708, New York, NY 10021 USA. Tel: +1 203 622 3033; fax: +203 625 9556; e-mail: groush@gcr0.com

Abbreviations: AMIL, amiloride; EPLER, eplerenone; PSDs, potassium sparing diuretics; SBP, systolic blood pressure; SPIR, spironolactone; TRIAM, triamterene

Received 23 July, 2015

Revised 26 August, 2015

Accepted 27 August, 2015

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.